| abstract |
REFERRING TO COMPOUNDS DERIVED FROM PYRIDAZINE OF FORMULA (Ia), WHERE X AND Y ARE 1; W IS C (O) NR1, NR1C (O), AMONG OTHERS; V IS C (O), C (O) O, C (S), AMONG OTHERS; R1 IS H, C1-C6 ALKYL, C2-C6 ALKYL, AMONG OTHERS; R2 IS C1-C12 ALKYL, C2-C12 ALKYL, AMONG OTHERS; R3 IS C1-C12 ALKYL, C2-C12 ALKYL, C1-C12 ALCOXY, AMONG OTHERS; R4 AND R5 ARE H, FLUORINE, CHLORINE, METHYL, METOXY, AMONG OTHERS; R6, R6a, R7, R7a, R8, R8a, R9 AND R9a ARE H OR C1-C3 ALKYL; R10 IS H O C1-C3 ALKYL; R12 IS H OR C1-C6 ALKYL. PREFERRED COMPOUNDS ARE: 6- [4- (2-ETHYLBUTYRIL) PIPERAZIN-1-IL] PYRIDAZINE-3-CARBOXYL ACID (2-CYCLOPROPYLETIL) AMIDE, 6- [4- (3,3,3-TRIFLUORO-2- METHYL-2-TRIFLUOROMETILPROPIONIL) PIPERAZIN-1-IL] PYRIDAZINE-3-CARBOXYL (2-CYCLOPROPYLETYL) AMIDE, 6- [4- (4,4,4-TRIFLUORO-3-TRIFLUOROMETILBUT-2-ENOYL) -PIPERAZIN- 1-IL] PYRIDAZINE-3-CARBOXYL (2-CYCLOPROPYL-ETHYL) AMIDE, AMONG OTHERS. SUCH COMPOUNDS ARE INHIBITORS OF ESTEAORIL-COA DESATURASE (SDC), PREFERENTIALLY, SDC1 AND ARE USEFUL IN THE TREATMENT OF DISEASES RELATED TO HIGH LEVELS OF LIPIDS, CARDIOVASCULAR DISEASES, METHODS, DIABETES |